Learn more about options for bladder cancer…
Treatment Options for Non-Muscle Invasive Bladder Cancer
Non-muscle invasive bladder cancer (NMIBC) is a common type of bladder cancer that has not spread into the muscle layer of the bladder wall. Effective management of NMIBC is crucial to reduce recurrence and progression rates. Treatment options vary widely but are often based on the stage and grade of the tumor.
BCG Therapy: The Gold Standard
Intravesical Bacillus Calmette-Guérin (BCG) therapy has long been considered the gold standard for treating NMIBC. BCG is a live bacterial vaccine that stimulates the immune system to attack bladder cancer cells. The treatment involves instilling BCG directly into the bladder, allowing it to provoke a localized immune response. Clinical studies have consistently shown that BCG reduces tumor recurrence significantly and improves overall outcomes for patients with high-grade NMIBC.
Typically, BCG is administered in a series of weekly treatments for six weeks, followed by maintenance therapy depending on individual risk factors. This approach has been proven to lower the chance of cancer returning and may even prevent cancer progression.
Emerging Treatments for BCG Failure
Despite BCG being the first-line treatment, approximately 30-50% of patients will experience a recurrence or progression of their disease after treatment. This presents a need for alternative options, particularly for those who become unresponsive to BCG.
One of the promising emerging treatments for BCG failure is Astilidrin, which is now FDA approved as an alternative for certain patients. As a novel treatment, Astilidrin aims to provide a new mechanism of action for patients who either cannot receive BCG due to side effects or those who have experienced recurrent tumors post-BCG. Early clinical results show promise, and ongoing trials are evaluating its efficacy and safety in comparison to standard therapies.
Expert Care at University Urology, PC
At University Urology, PC, we pride ourselves on providing advanced general and subspecialty urology care in East Tennessee and beyond. Our team of fellowship-trained urologists specializes in a wide range of urologic conditions, including NMIBC. We are committed to staying at the forefront of urologic advancements, including emerging treatment options like Astilidrin.
Our clinic offers comprehensive evaluation and treatment planning tailored to each patient's unique needs. We understand the challenges that come with NMIBC and are dedicated to promoting the best overall urologic health and quality of life for our patients.
If you or a loved one is facing a diagnosis of non-muscle invasive bladder cancer, we invite you to contact us for a consultation. Our experienced team is here to support you on your journey to better health.